摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-acetylpyrrole-4-carbonitrile | 80242-22-4

中文名称
——
中文别名
——
英文名称
2-acetylpyrrole-4-carbonitrile
英文别名
5-acetyl-1H-pyrrole-3-carbonitrile;4-cyano-2-acetylpyrrole
2-acetylpyrrole-4-carbonitrile化学式
CAS
80242-22-4
化学式
C7H6N2O
mdl
MFCD12923691
分子量
134.137
InChiKey
YDLGEEKPFZUAPP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    190.5-191 °C
  • 沸点:
    316.1±27.0 °C(Predicted)
  • 密度:
    1.22±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    56.6
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-acetylpyrrole-4-carbonitrile 在 palladium on activated charcoal 哌啶氢气 作用下, 以 甲醇乙醇 为溶剂, 110.0 ℃ 、275.8 kPa 条件下, 生成
    参考文献:
    名称:
    Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517
    摘要:
    Based on the lead compound BX-517, a series of C-4 ' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4 ' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.05.060
  • 作为产物:
    描述:
    氯磺酰异氰酸酯2-乙酰基吡咯 以 DMF (N,N-dimethyl-formamide) 、 乙腈 为溶剂, 反应 2.67h, 生成 2-acetylpyrrole-4-carbonitrile
    参考文献:
    名称:
    Indolinone derivatives and their use in treating disease-states such as cancer
    摘要:
    Indolinone衍生物,例如公式(I)中的化合物:其中A,m,n,R1,R2,R3,R5和R6如本文所述,据本文披露,可用于治疗通过抑制PDK-1活性缓解疾病状态的哺乳动物。
    公开号:
    US20050090541A1
点击查看最新优质反应信息

文献信息

  • Indolinone derivatives and their use in treating disease-states such as cancer
    申请人:Arnaiz Damian
    公开号:US20050090541A1
    公开(公告)日:2005-04-28
    Indolinone derivatives, such as compounds of the formula (I): wherein A, m, n, R 1 , R 2 , R 3 , R 5 and R 6 are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.
    Indolinone衍生物,例如公式(I)中的化合物:其中A,m,n,R1,R2,R3,R5和R6如本文所述,据本文披露,可用于治疗通过抑制PDK-1活性缓解疾病状态的哺乳动物。
  • NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES
    申请人:GALAPAGOS NV
    公开号:US20160297830A1
    公开(公告)日:2016-10-13
    Compounds are disclosed that have a formula represented by the following: wherein A, B, R 1 , R 2 and R 3 are as defined herein. Novel compounds of the invention may be prepared as a pharmaceutical composition, and may be useful in the treatment of infectious diseases, in particular bacterial infectious diseases. The compounds may be active against a specific enzyme in the bacterial DNA replicative process, DNA polymerase IIIE.
    本发明揭示了具有以下表示的化合物:其中A、B、R1、R2和R3如本文所定义。本发明的新化合物可以制备为药物组合物,并且可能在治疗传染病方面有用,特别是细菌性传染病。这些化合物可能对细菌DNA复制过程中的特定酶DNA聚合酶IIIE具有活性。
  • PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS
    申请人:Webber E. Stephen
    公开号:US20080031852A1
    公开(公告)日:2008-02-07
    The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    该发明涉及吡咯[1,2-b]吡嗪酮类化合物和含有这些化合物的药物组合物,可用于治疗丙型肝炎病毒感染。
  • COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS
    申请人:Wan Yongqin
    公开号:US20110263610A1
    公开(公告)日:2011-10-27
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
    本发明提供了一类新型化合物,包括含有这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的B细胞活动相关的疾病或障碍的方法,特别是涉及到肌醇1,4,5-三磷酸3-激酶B(ITPKb)异常激活的疾病或障碍。
  • [EN] COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS D'ITPKB
    申请人:IRM LLC
    公开号:WO2009123948A3
    公开(公告)日:2009-11-26
查看更多